Stockscreener 앱 받기
10.19
0.83%
-0.10
전일 마감가:
$10.29
열려 있는:
$10.29
하루 거래량:
1.54M
Relative Volume:
0.39
시가총액:
$2.89B
수익:
-
순이익/손실:
$-125.04M
주가수익비율:
-12.43
EPS:
-0.82
순현금흐름:
$-122.99M
1주 성능:
+6.08%
1개월 성능:
+201.03%
6개월 성능:
+496.78%
1년 성능:
+412.81%
1일 변동 폭
$10.10
$10.48
1주일 범위
$8.77
$10.67
52주 변동 폭
$1.01
$10.67
Erasca Inc Stock (ERAS) Company Profile
명칭
Erasca Inc
전화
(858) 465-6511
주소
3115 MERRYFIELD ROW, SAN DIEGO
ERAS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ERAS
Erasca Inc
|
10.20 | 2.92B | 0 | -125.04M | -122.99M | -0.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.03 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
753.68 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
830.75 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
362.13 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
342.31 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Erasca Inc Stock (ERAS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-07 | 개시 | Piper Sandler | Overweight |
| 2025-10-16 | 개시 | Stifel | Buy |
| 2025-09-03 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2025-08-18 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-26 | 개시 | Raymond James | Outperform |
| 2024-11-18 | 개시 | Jefferies | Buy |
| 2024-03-11 | 개시 | CapitalOne | Overweight |
| 2024-01-05 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-10-11 | 개시 | H.C. Wainwright | Buy |
| 2023-03-30 | 개시 | Mizuho | Buy |
| 2023-02-24 | 개시 | Goldman | Buy |
| 2023-02-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
모두보기
Erasca Inc 주식(ERAS)의 최신 뉴스
Erasca stock hits 52-week high at 10.46 USD By Investing.com - Investing.com Nigeria
Erasca Announces Major Underwritten Public Equity Offering - TipRanks
Erasca, Inc. Announces Upsized Public Offering of Common Stock - TradingView — Track All Markets
Erasca raises $225M to sharpen RAS oncology focus - BioWorld MedTech
Latham & Watkins Advises Erasca in Upsized US$225 Million Offering of Common Stock - Latham & Watkins LLP
Erasca prices $225M stock offering at $10 per share - MSN
A trio of biotechs targets $500M+ offerings - Endpoints News
Erasca stock hits 52-week high at 10.46 USD - Investing.com
Top 2 Tech Stocks That Are Ticking Portfolio Bombs - Benzinga
Erasca Announces Pricing of Upsized Public Offering of Common Stock - The Manila Times
Erasca, Inc. Announces Pricing of $225 Million Public Offering of Common Stock - Quiver Quantitative
Cancer drug developer Erasca raises $225M in stock sale - Stock Titan
Erasca Announces Pricing of Upsized Public Offering of Common Stock - GlobeNewswire Inc.
Top 2 Industrials Stocks That May Collapse In Q1 - Benzinga
Netflix, Erasca, Kraft Heinz And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Erasca plans to raise $150 million in public stock offering By Investing.com - Investing.com Nigeria
Erasca Announces $150 Million Public Offering; Stock Down - Nasdaq
Erasca Stock Pre-Market (-8.3%) : Announces $150M Public Stock Offering - Trefis
Erasca plans $150M public stock offering - MSN
Erasca stock falls after announcing $150 million public offering - Investing.com
Erasca announces proposed public offering of $150 million of common stock - marketscreener.com
Erasca (ERAS) Stock Slides After The Bell: Here's Why - Benzinga
Erasca (ERAS) Announces $150M Public Offering to Fund Cancer Research - Intellectia AI
Erasca reports preliminary year-end cash and securities of $341.8 million - Investing.com
Erasca, Inc. Announces Proposed Public Offering of $150 Million in Common Stock - Quiver Quantitative
Erasca Announces Proposed Public Offering of $150 Million of Common Stock - The Manila Times
Cancer drug developer Erasca plans $150M stock sale to fund R&D - Stock Titan
Erasca (ERAS) Soars 42% on Bullish Rating, PT Upgrade - Finviz
Erasca (ERAS) touches 3-year high as 4 analysts go bullish; gets 267% PT hike - MSN
Do Early ERAS-0015 Data Reframe Erasca’s (ERAS) Ambitions in RAS-Targeted Oncology? - simplywall.st
Erasca stock surges 42% in a week: Here's what you should know - MSN
Erasca (ERAS) Valuation Comes Into Focus After Early ERAS-0015 Data At JP Morgan Healthcare Conference - simplywall.st
Erasca Offers $7.50 Put Option, Attracting Investor Interest - Intellectia AI
Erasca (ERAS) Touches 3-Year High as 4 Analysts Go Bullish; Gets 267% PT Hike - Finviz
Erasca price target raised to $11 from $5 at Piper Sandler - TipRanks
Erasca Stock Surges 42% in a Week: Here's What You Should Know - Finviz
Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape - PR Newswire
HC Wainwright Has Strong Estimate for Erasca FY2027 Earnings - Defense World
Winners Losers: What is AXIS Capital Holdings Limiteds debt to equity ratioAnalyst Downgrade & Fast Gain Stock Tips - baoquankhu1.vn
Assessing Erasca (ERAS) Valuation After Encouraging Early ERAS-0015 Data At JP Morgan Conference - Yahoo Finance
Erasca Rallies Amid Acquisition Talks and Positive Price Target Revisions - StocksToTrade
Clear Street Elevates Erasca: Price Target Stands Tall at $11 - timothysykes.com
FY2027 Earnings Forecast for Erasca Issued By HC Wainwright - MarketBeat
Erasca (ERAS) Is Up 60.7% After Early ERAS-0015 Data Highlights Pan-RAS Franchise Ambitions - Yahoo Finance
Erasca (ERAS) Hits Fresh High Anew as Firm Gets up to 267% PT Hike - Insider Monkey
10 Stock With Eye-Popping Gains; 5 Are on Fresh Highs - Insider Monkey
Erasca stock hits 52-week high at 8.33 USD By Investing.com - Investing.com Nigeria
Erasca (NASDAQ:ERAS) Trading Up 7.7% Following Analyst Upgrade - Defense World
Erasca (ERAS) Price Target Increased by 30.91% to 6.53 - Nasdaq
Erasca stock jumps 10% as Wall Street lifts targets to $11 on ERAS-0015 data - TechStock²
Erasca stock hits 52-week high at 8.33 USD - Investing.com
Erasca Inc (ERAS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.42%
1.60%
자본화:
|
볼륨(24시간):